CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: APOBEC3F (ImmuneEditome ID:200316)

1. Gene summary of enriched editing regions for APOBEC3F

check button Gene summary
Gene informationGene symbol

APOBEC3F

Gene ID

200316

GeneSynonymsA3F|ARP8|BK150C2.4.MRNA|KA6
GeneCytomap

22q13.1

GeneTypeprotein-coding
GeneDescriptionDNA dC->dU-editing enzyme APOBEC-3F|apolipoprotein B editing enzyme catalytic polypeptide-like 3F|apolipoprotein B mRNA editing enzyme cytidine deaminase|apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3F|induced upon T-cell activation
GeneModificationdate20230518
UniprotIDQ8IUX4
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr22:39043328-39044064:+ENST00000491387.1ENSG00000128394.15APOBEC3FncRNA_intronicMER33,AluSq2chr22:39043328-39044064:+.alignment
chr22:39048422-39048784:+ENST00000476513.1ENSG00000128394.15APOBEC3FncRNA_intronicAluSc8,AluSgchr22:39048422-39048784:+.alignment
chr22:39052977-39055522:+ENST00000308521.8ENSG00000128394.15APOBEC3FUTR3AluSg,AluSx,AluJb,AluSp,AluSx1,MLT1B,MER65Cchr22:39052977-39055522:+.alignment


Top

2. Tumor-specific enriched editing regions for APOBEC3F


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr22:39052977-39055522:+KIRCEER3.8392e-04image
ENSG00000128394.15,APOBEC3FKIRCEAG2.1693e-03image
chr22:39052977-39055522:+LUSCEER3.4988e-03image
ENSG00000128394.15,APOBEC3FLUSCEAG2.4257e-03image
chr22:39052977-39055522:+PRADEER1.3851e-04image
ENSG00000128394.15,APOBEC3FPRADEAG1.4379e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr22:39052977-39055522:+MESOEER3.4300e-022.6558e-024.9443e+02image
chr22:39052977-39055522:+OVEER7.6275e-034.1248e-027.6211e+00image
ENSG00000128394.15,APOBEC3FSKCMEAG2.9651e-028.0871e-034.1094e+01image
chr22:39052977-39055522:+THYMEER1.0825e-022.3933e-023.1449e+32image

Top

3. Enriched editing regions and immune related genes for APOBEC3F


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr22:39052977-39055522:+ESCAEERENSG00000128394,APOBEC3F-0.48841.9888e-051.3703e-10-0.5186imageNCSTF2T;DDX3X;DHX9;ELAVL1;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;NOP56;NOP58;PRPF8;RBFOX2;SAFB2;SND1;SRSF3;TAF15;TARDBP;U2AF1;U2AF2NANeutrophilsGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr22:39052977-39055522:+ESCAEERENSG00000100209,HSCB-0.48692.3309e-056.0651e-08-0.4472imageNCSTF2T;DDX3X;DGCR8;DHX9;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;KHSRP;NOP56;NOP58;PRPF8;RBFOX2;SAFB2;SF3A3;SND1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1NAGSVA_HALLMARK_MYC_TARGETS_V1
chr22:39052977-39055522:+ESCAEERENSG00000100263,RHBDD3-0.44842.0128e-045.2649e-08-0.4490imageNCNBP;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;KHSRP;NONO;NOP56;NOP58;PRPF8;RBFOX2;SAFB2;SF3A3;SND1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;U2AF1;U2AF2;UPF1NAGSVA_HALLMARK_E2F_TARGETS
chr22:39052977-39055522:+OVEERENSG00000128394,APOBEC3F-0.44041.0291e-093.9396e-12-0.4130imageNCSTF2T;DDX3X;DHX9;ELAVL1;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;NOP56;NOP58;PRPF8;RBFOX2;SAFB2;SND1;SRSF3;TAF15;TARDBP;U2AF1;U2AF2NAEosinophilsGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr22:39052977-39055522:+UVMEERENSG00000137460,FHDC1-0.57646.2670e-041.1719e-05-0.5328imageNCSTF2T;DGCR8;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;KHSRP;NONO;NOP56;NOP58;RBFOX2;SRSF3;TAF15;TARDBP;U2AF2;UPF1NAT_cells_CD8GSVA_HALLMARK_NOTCH_SIGNALING
chr22:39052977-39055522:+UVMEERENSG00000176974,SHMT1-0.56826.4940e-049.7684e-06-0.5369imageNCNBP;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;KHSRP;NONO;NOP56;NOP58;PRPF8;QKI;RBFOX2;SAFB2;SF3A3;SND1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1NAT_cells_CD4_memory_activatedGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
chr22:39052977-39055522:+UVMEERENSG00000135905,DOCK10-0.56688.1774e-045.0360e-04-0.4356imageNCSTF2T;EIF4A3;ELAVL1;ELAVL3;FBL;HNRNPA1;HNRNPC;HNRNPL;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;TIA1;TIAL1;U2AF2;UPF1DOCK10T_cells_CD8GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr22:39052977-39055522:+UVMEERENSG00000144029,MRPS5-0.58158.3811e-047.1934e-07-0.5895imageNCNBP;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;KHSRP;NONO;NOP56;NOP58;PRPF8;RBFOX2;SAFB2;SF3A3;SND1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1NAT_cells_follicular_helperGSVA_HALLMARK_MTORC1_SIGNALING
chr22:39052977-39055522:+UVMEERENSG00000139180,NDUFA9-0.56581.0256e-032.3015e-05-0.5174imageNCNBP;CSTF2T;DDX3X;DDX42;DGCR8;EIF4A3;ELAVL1;ELAVL3;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;KHSRP;NONO;NOP56;NOP58;PRPF8;QKI;RBFOX2;SAFB2;SF3A3;SND1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1NAT_cells_CD8GSVA_HALLMARK_MTORC1_SIGNALING
chr22:39052977-39055522:+UVMEERENSG00000270504,RP11-420L9.50.51671.7624e-031.7827e-040.4655imageNCSTF2T;EIF4A3;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPUL1;IGF2BP1;IGF2BP2;PRPF8;RBFOX2;SF3A3;SND1;SRSF3;SRSF7;TAF15;TIA1;TIAL1;U2AF1;U2AF2;UPF1NAMacrophages_M1GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for APOBEC3F


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000128394.15,APOBEC3F
TGCTEAGMEXENSG00000221926.7chr1715642720:15642816:15651090:15651941:15658801:15658876:15677175:15677277-0.35757.6599e-033.2041e-06-0.4572imageNADAR;BUD13;CSTF2T;DDX3X;DHX9;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;U2AF1;U2AF2;XRN2;YTHDC1;ZNF184TRIM16B_cells_naiveGSVA_HALLMARK_HYPOXIA
chr22:39052977-39055522:+
TGCTEERIRENSG00000075415.8chr1298593590:98593740:98593978:985940240.38337.2303e-032.4398e-060.4433imageNCNBP;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;KHSRP;NONO;NOP56;NOP58;PRPF8;QKI;RBFOX2;SAFB2;SF3A3;SND1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr22:39052977-39055522:+
TGCTEERA5ENSG00000164880.11chr71483741:1483853:1484002:1484113:1483950:1484113-0.17481.6456e-023.5509e-06-0.4312imageNCNBP;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;KHSRP;NONO;NOP56;NOP58;PRPF8;RBFOX2;SAFB2;SF3A3;SND1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;U2AF1;U2AF2;UPF1NAGSVA_HALLMARK_PEROXISOME
ENSG00000128394.15,APOBEC3F
TGCTEAGESENSG00000082213.13chr531545670:31545712:31548489:31548687:31551292:315513940.31268.3040e-031.3350e-050.4712imageNADAR;BUD13;CSTF2T;DDX3X;DHX9;DICER1;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LIN28;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM27;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;U2AF1;U2AF2;XRN2;YTHDC1;ZNF184NAB_cells_naiveGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
ENSG00000128394.15,APOBEC3F
TGCTEAGIRENSG00000120314.14chr5140669332:140669690:140671268:140672344-0.35802.4916e-025.9324e-06-0.4167imageNADAR;BUD13;CSTF2T;DDX3X;DHX9;DICER1;ELAVL1;FAM120A;FBL;FUS;FXR1;GNL3;HNRNPA1;HNRNPC;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM27;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;U2AF1;U2AF2;XRN2;YTHDC1;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
ENSG00000128394.15,APOBEC3F
TGCTEAGIRENSG00000060138.8chr1210710350:10710788:10713210:107133330.30864.6712e-025.3921e-050.4040imageNADAR;BUD13;CSTF2T;DDX3X;DHX9;ELAVL1;FAM120A;FBL;FUS;FXR1;GNL3;HNRNPA1;HNRNPC;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM27;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;U2AF1;U2AF2;XRN2;YTHDC1;ZNF184NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY
ENSG00000128394.15,APOBEC3F
TGCTEAGIRENSG00000184083.7chrX54173788:54174146:54182499:541827780.32441.1750e-024.2688e-050.4460imageNADAR;BUD13;CSTF2T;DDX3X;DHX9;DICER1;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;SAFB2;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;U2AF1;U2AF2;YTHDC1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr22:39052977-39055522:+
TGCTEERESENSG00000168488.14chr1628836058:28836122:28836325:28836490:28836727:288369190.33512.9457e-025.6717e-060.4141imageNCNBP;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;KHSRP;NONO;NOP56;NOP58;PRPF8;QKI;RBFOX2;SAFB2;SF3A3;SND1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1NAB_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000128394.15,APOBEC3F
TGCTEAGIRENSG00000072201.9chr453459300:53461042:53461434:534615930.37571.2796e-026.5128e-060.4205imageNADAR;CSTF2T;DDX3X;DHX9;ELAVL1;FBL;FUS;FXR1;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;ILF3;LIN28B;NOP56;NOP58;PRPF8;RBFOX2;SRSF1;SRSF3;TAF15;TARDBP;U2AF2;XRN2;YTHDC1NAT_cells_follicular_helperGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr22:39052977-39055522:+
TGCTEERIRENSG00000123154.7chr1912672272:12672914:12673007:126731160.40905.8319e-033.1318e-070.4610imageNCNBP;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPC;HNRNPK;HNRNPU;HNRNPUL1;IGF2BP2;NONO;NOP56;NOP58;PRPF8;RBFOX2;SAFB2;SF3A3;SND1;TAF15;TARDBP;U2AF1;U2AF2;UPF1NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for APOBEC3F


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr22:39052977-39055522:+ACCEERT_cells_CD4_memory_resting5.8504e-030.5351image
ENSG00000128394.15,APOBEC3FACCEAGT_cells_CD4_memory_resting2.9589e-030.5696image
chr22:39043328-39044064:+BLCAEERT_cells_CD4_memory_activated5.8183e-030.3578image
chr22:39052977-39055522:+BLCAEERMacrophages_M12.4884e-050.2448image
ENSG00000128394.15,APOBEC3FBLCAEAGMacrophages_M19.0162e-050.2245image
chr22:39043328-39044064:+BRCAEERMast_cells_resting2.3182e-040.3442image
chr22:39052977-39055522:+BRCAEERMast_cells_resting3.8160e-070.1848image
ENSG00000128394.15,APOBEC3FBRCAEAGMast_cells_resting8.3490e-080.1945image
chr22:39043328-39044064:+CESCEERT_cells_CD84.2815e-020.3179image
chr22:39052977-39055522:+CESCEERB_cells_naive3.2075e-02-0.1446image
ENSG00000128394.15,APOBEC3FCESCEAGB_cells_naive5.3224e-03-0.1877image
chr22:39052977-39055522:+CHOLEERNeutrophils4.3527e-02-0.3710image
chr22:39052977-39055522:+COADEERMast_cells_activated7.1337e-030.3557image
ENSG00000128394.15,APOBEC3FCOADEAGMast_cells_activated1.3724e-020.3305image
chr22:39048422-39048784:+ESCAEERT_cells_regulatory_(Tregs)3.8110e-020.4666image
chr22:39043328-39044064:+GBMEERDendritic_cells_resting1.7427e-020.3651image
chr22:39052977-39055522:+GBMEERT_cells_CD4_naive1.0397e-020.3703image
ENSG00000128394.15,APOBEC3FGBMEAGDendritic_cells_resting2.1639e-020.2867image
chr22:39052977-39055522:+HNSCEERT_cells_regulatory_(Tregs)2.6377e-03-0.1787image
ENSG00000128394.15,APOBEC3FHNSCEAGT_cells_regulatory_(Tregs)2.6511e-03-0.1780image
chr22:39043328-39044064:+KIRCEERNK_cells_activated1.6045e-020.3047image
chr22:39052977-39055522:+KIRCEERMast_cells_resting1.4135e-040.2065image
ENSG00000128394.15,APOBEC3FKIRCEAGMast_cells_resting2.0502e-030.1664image
chr22:39048422-39048784:+KIRPEERT_cells_regulatory_(Tregs)4.0017e-02-0.4133image
chr22:39052977-39055522:+KIRPEERNK_cells_activated3.9764e-03-0.2192image
ENSG00000128394.15,APOBEC3FKIRPEAGT_cells_CD84.9433e-02-0.1416image
ENSG00000128394.15,APOBEC3FLAMLEAGMonocytes2.1814e-030.3681image
ENSG00000128394.15,APOBEC3FLGGEAGEosinophils7.0459e-030.4670image
chr22:39052977-39055522:+LIHCEERT_cells_CD4_naive1.7655e-060.3590image
ENSG00000128394.15,APOBEC3FLIHCEAGT_cells_CD4_naive2.8614e-060.3521image
chr22:39052977-39055522:+LUADEERT_cells_gamma_delta2.0129e-030.1810image
ENSG00000128394.15,APOBEC3FLUADEAGT_cells_gamma_delta1.9416e-020.1374image
chr22:39043328-39044064:+LUSCEERB_cells_memory1.7477e-020.3315image
chr22:39052977-39055522:+LUSCEERT_cells_CD4_memory_activated8.6625e-030.1361image
ENSG00000128394.15,APOBEC3FLUSCEAGT_cells_CD4_memory_resting8.6904e-03-0.1348image
chr22:39043328-39044064:+OVEERT_cells_gamma_delta1.0500e-02-0.3107image
chr22:39048422-39048784:+OVEERB_cells_naive4.5758e-020.1859image
chr22:39052977-39055522:+OVEERMacrophages_M02.0277e-02-0.1439image
ENSG00000128394.15,APOBEC3FOVEAGMacrophages_M01.1178e-02-0.1568image
chr22:39052977-39055522:+PAADEERDendritic_cells_activated2.9368e-030.2974image
ENSG00000128394.15,APOBEC3FPAADEAGDendritic_cells_activated8.7914e-040.3292image
ENSG00000128394.15,APOBEC3FPCPGEAGDendritic_cells_resting7.3295e-030.2840image
chr22:39043328-39044064:+PRADEERMacrophages_M11.5671e-030.3566image
chr22:39052977-39055522:+PRADEERMacrophages_M28.6250e-040.2016image
ENSG00000128394.15,APOBEC3FPRADEAGMacrophages_M27.3554e-030.1601image
chr22:39052977-39055522:+SARCEEREosinophils4.1728e-030.2246image
ENSG00000128394.15,APOBEC3FSARCEAGNeutrophils1.8869e-020.1843image
chr22:39043328-39044064:+SKCMEERMast_cells_resting4.1942e-02-0.3273image
chr22:39052977-39055522:+SKCMEERDendritic_cells_resting6.5695e-040.1922image
ENSG00000128394.15,APOBEC3FSKCMEAGDendritic_cells_resting1.6618e-040.2113image
chr22:39052977-39055522:+STADEEREosinophils3.7689e-060.2905image
ENSG00000128394.15,APOBEC3FSTADEAGEosinophils2.1150e-050.2686image
chr22:39052977-39055522:+TGCTEERNK_cells_activated1.0912e-02-0.2397image
ENSG00000128394.15,APOBEC3FTGCTEAGNK_cells_activated6.8747e-03-0.2563image
chr22:39043328-39044064:+THCAEERNK_cells_resting1.6204e-030.2194image
chr22:39052977-39055522:+THCAEERMacrophages_M12.5287e-03-0.1504image
ENSG00000128394.15,APOBEC3FTHCAEAGEosinophils5.5471e-040.1686image
chr22:39043328-39044064:+THYMEERNK_cells_resting9.2005e-03-0.4067image
chr22:39052977-39055522:+THYMEERMacrophages_M01.6191e-020.2219image
ENSG00000128394.15,APOBEC3FTHYMEAGMacrophages_M02.3687e-020.2091image
chr22:39043328-39044064:+UCECEERMacrophages_M21.8553e-020.3224image
ENSG00000128394.15,APOBEC3FUCECEAGMacrophages_M21.7075e-020.2035image
chr22:39052977-39055522:+UCSEERMacrophages_M21.2419e-02-0.4508image
ENSG00000128394.15,APOBEC3FUVMEAGT_cells_CD84.1952e-02-0.2613image


Top

6. Enriched editing regions and immune gene sets for APOBEC3F


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr22:39052977-39055522:+ACCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.6434e-02-0.4019image
ENSG00000128394.15,APOBEC3FACCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.0685e-02-0.4120image
chr22:39043328-39044064:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.0819e-020.3323image
chr22:39052977-39055522:+BLCAGSVA_HALLMARK_HYPOXIAEER2.1997e-060.2738image
ENSG00000128394.15,APOBEC3FBLCAGSVA_HALLMARK_HYPOXIAEAG7.3256e-060.2560image
chr22:39043328-39044064:+BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.2551e-030.2883image
chr22:39052977-39055522:+BRCAGSVA_HALLMARK_MYOGENESISEER2.8152e-050.1528image
ENSG00000128394.15,APOBEC3FBRCAGSVA_HALLMARK_MYOGENESISEAG3.1159e-050.1518image
chr22:39052977-39055522:+CESCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.3924e-02-0.1656image
ENSG00000128394.15,APOBEC3FCESCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.3548e-03-0.2045image
chr22:39043328-39044064:+CESCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.6283e-020.3469image
ENSG00000128394.15,APOBEC3FCHOLGSVA_HALLMARK_P53_PATHWAYEAG3.2817e-02-0.3843image
ENSG00000128394.15,APOBEC3FCOADGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.8101e-020.3177image
ENSG00000128394.15,APOBEC3FESCAGSVA_HALLMARK_E2F_TARGETSEAG2.8789e-03-0.2537image
chr22:39052977-39055522:+ESCAGSVA_HALLMARK_KRAS_SIGNALING_UPEER4.2909e-030.2452image
ENSG00000128394.15,APOBEC3FGBMGSVA_HALLMARK_SPERMATOGENESISEAG1.2273e-02-0.3113image
chr22:39052977-39055522:+GBMGSVA_HALLMARK_E2F_TARGETSEER2.0951e-02-0.3360image
chr22:39043328-39044064:+GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.7161e-02-0.3659image
ENSG00000128394.15,APOBEC3FHNSCGSVA_HALLMARK_P53_PATHWAYEAG1.4843e-030.1880image
chr22:39052977-39055522:+HNSCGSVA_HALLMARK_P53_PATHWAYEER4.3336e-040.2085image
chr22:39043328-39044064:+KIRCGSVA_HALLMARK_DNA_REPAIREER3.5436e-020.2677image
ENSG00000128394.15,APOBEC3FKIRCGSVA_HALLMARK_E2F_TARGETSEAG3.7545e-04-0.1915image
chr22:39052977-39055522:+KIRCGSVA_HALLMARK_ANGIOGENESISEER2.3436e-050.2289image
ENSG00000128394.15,APOBEC3FLAMLGSVA_HALLMARK_HYPOXIAEAG6.5559e-030.3290image
chr22:39052977-39055522:+LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER7.0605e-040.2588image
ENSG00000128394.15,APOBEC3FLIHCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.4247e-03-0.2442image
ENSG00000128394.15,APOBEC3FLUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.1195e-020.1202image
chr22:39052977-39055522:+LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER4.3018e-020.1191image
chr22:39052977-39055522:+LUSCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER6.5424e-040.1762image
chr22:39043328-39044064:+LUSCGSVA_HALLMARK_APICAL_SURFACEEER2.8070e-020.3077image
ENSG00000128394.15,APOBEC3FLUSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG6.7054e-04-0.1742image
ENSG00000128394.15,APOBEC3FMESOGSVA_HALLMARK_HYPOXIAEAG1.9502e-020.3471image
chr22:39052977-39055522:+MESOGSVA_HALLMARK_HYPOXIAEER1.2440e-020.3697image
chr22:39048422-39048784:+OVGSVA_HALLMARK_MYC_TARGETS_V1EER4.6397e-040.3199image
chr22:39052977-39055522:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.2001e-040.2138image
chr22:39043328-39044064:+OVGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.0478e-030.3702image
ENSG00000128394.15,APOBEC3FOVGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.0626e-06-0.2724image
ENSG00000128394.15,APOBEC3FPAADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.6620e-04-0.3511image
chr22:39052977-39055522:+PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.6360e-04-0.3530image
ENSG00000128394.15,APOBEC3FPCPGGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.8261e-040.3780image
chr22:39052977-39055522:+PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.8516e-02-0.1333image
ENSG00000128394.15,APOBEC3FPRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.1773e-02-0.1506image
chr22:39043328-39044064:+PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.1649e-030.3343image
chr22:39052977-39055522:+SARCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER5.1999e-030.2192image
ENSG00000128394.15,APOBEC3FSKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.0897e-02-0.1437image
chr22:39052977-39055522:+SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.2309e-03-0.1728image
chr22:39043328-39044064:+SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.2937e-030.4474image
ENSG00000128394.15,APOBEC3FSTADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.7942e-020.1330image
chr22:39052977-39055522:+STADGSVA_HALLMARK_HYPOXIAEER1.6864e-020.1526image
ENSG00000128394.15,APOBEC3FTGCTGSVA_HALLMARK_P53_PATHWAYEAG5.2872e-08-0.4906image
chr22:39052977-39055522:+TGCTGSVA_HALLMARK_P53_PATHWAYEER6.4742e-08-0.4839image
chr22:39052977-39055522:+THCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.8319e-04-0.1804image
ENSG00000128394.15,APOBEC3FTHCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG5.9957e-06-0.2199image
chr22:39043328-39044064:+THCAGSVA_HALLMARK_DNA_REPAIREER4.2109e-020.1424image
chr22:39052977-39055522:+THYMGSVA_HALLMARK_TGF_BETA_SIGNALINGEER5.6342e-030.2544image
chr22:39043328-39044064:+THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER2.2878e-040.5510image
ENSG00000128394.15,APOBEC3FUCECGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.4901e-030.2479image
chr22:39043328-39044064:+UCECGSVA_HALLMARK_HEME_METABOLISMEER4.0148e-030.3888image
ENSG00000128394.15,APOBEC3FUVMGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG2.6814e-03-0.3778image
chr22:39052977-39055522:+UVMGSVA_HALLMARK_PEROXISOMEEER1.7792e-03-0.3952image


Top

7. Enriched editing regions and drugs for APOBEC3F


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr22:39052977-39055522:+ACCCytarabineEER3.2254e-020.4292image
ENSG00000128394.15,APOBEC3FACCCamptothecinEAG2.3646e-020.4510image
chr22:39043328-39044064:+BLCABryostatin.1EER5.6369e-030.3591image
ENSG00000128394.15,APOBEC3FBLCACisplatinEAG4.9883e-06-0.2605image
chr22:39052977-39055522:+BLCACisplatinEER1.0895e-07-0.3057image
chr22:39052977-39055522:+BRCAABT.888EER9.5977e-070.1784image
chr22:39043328-39044064:+BRCAABT.263EER4.2536e-020.1938image
ENSG00000128394.15,APOBEC3FBRCABryostatin.1EAG1.0692e-06-0.1775image
ENSG00000128394.15,APOBEC3FCESCAZD6244EAG7.3620e-03-0.1806image
chr22:39052977-39055522:+CESCEmbelinEER4.9060e-04-0.2331image
ENSG00000128394.15,APOBEC3FCOADIPA.3EAG1.0378e-030.4304image
chr22:39052977-39055522:+COADJNK.9LEER1.2431e-030.4207image
ENSG00000128394.15,APOBEC3FESCACI.1040EAG1.6057e-03-0.2680image
chr22:39052977-39055522:+ESCACI.1040EER9.5232e-05-0.3307image
chr22:39052977-39055522:+GBMAKT.inhibitor.VIIIEER4.1915e-020.2980image
ENSG00000128394.15,APOBEC3FHNSCLapatinibEAG4.1948e-06-0.2734image
chr22:39052977-39055522:+HNSCLapatinibEER3.4727e-07-0.3025image
chr22:39052977-39055522:+KIRCAS601245EER2.5301e-04-0.1987image
ENSG00000128394.15,APOBEC3FKIRCAS601245EAG1.3101e-03-0.1734image
chr22:39043328-39044064:+KIRCJNK.9LEER6.2740e-03-0.3435image
chr22:39052977-39055522:+KIRPCyclopamineEER3.6269e-030.2213image
chr22:39048422-39048784:+KIRPAUY922EER1.4374e-020.4834image
ENSG00000128394.15,APOBEC3FLAMLDoxorubicinEAG1.3656e-030.3833image
ENSG00000128394.15,APOBEC3FLGGAG.014699EAG3.9196e-02-0.3663image
chr22:39052977-39055522:+LIHCBleomycinEER3.1738e-040.2794image
ENSG00000128394.15,APOBEC3FLIHCBleomycinEAG1.4964e-030.2468image
ENSG00000128394.15,APOBEC3FLUADAZD6482EAG4.5839e-030.1666image
chr22:39052977-39055522:+LUADABT.888EER2.7176e-030.1757image
chr22:39043328-39044064:+LUADBI.2536EER3.7918e-030.6032image
chr22:39052977-39055522:+LUSCBMS.536924EER3.9529e-04-0.1833image
ENSG00000128394.15,APOBEC3FLUSCBMS.536924EAG1.1783e-03-0.1665image
chr22:39052977-39055522:+MESOABT.888EER2.4622e-020.3347image
ENSG00000128394.15,APOBEC3FMESODoxorubicinEAG2.4286e-02-0.3354image
chr22:39043328-39044064:+OVCisplatinEER2.2689e-03-0.3668image
ENSG00000128394.15,APOBEC3FOVAZD6482EAG9.1307e-090.3469image
chr22:39048422-39048784:+OVDocetaxelEER2.6650e-03-0.2764image
chr22:39052977-39055522:+OVAZ628EER1.1506e-04-0.2369image
chr22:39052977-39055522:+PAADCGP.60474EER2.3299e-020.2290image
ENSG00000128394.15,APOBEC3FPAADCGP.60474EAG2.5739e-020.2241image
ENSG00000128394.15,APOBEC3FPCPGAG.014699EAG5.1200e-030.2959image
chr22:39043328-39044064:+PRADJNK.Inhibitor.VIIIEER5.6802e-03-0.3144image
chr22:39052977-39055522:+PRADAZD7762EER9.5507e-030.1575image
ENSG00000128394.15,APOBEC3FPRADAZD7762EAG5.9910e-030.1642image
ENSG00000128394.15,APOBEC3FSARCMidostaurinEAG3.0497e-03-0.2314image
chr22:39052977-39055522:+SARCAxitinibEER1.1193e-03-0.2546image
chr22:39052977-39055522:+SKCMFTI.277EER2.9506e-04-0.2039image
ENSG00000128394.15,APOBEC3FSKCMFTI.277EAG6.8835e-05-0.2230image
chr22:39043328-39044064:+SKCMEHT.1864EER2.5397e-030.4699image
chr22:39052977-39055522:+STADCGP.60474EER1.7536e-050.2706image
ENSG00000128394.15,APOBEC3FSTADCGP.60474EAG3.6507e-060.2915image
chr22:39052977-39055522:+TGCTMG.132EER4.4175e-050.3759image
ENSG00000128394.15,APOBEC3FTGCTMG.132EAG6.7687e-050.3705image
chr22:39052977-39055522:+THCAAZD6244EER1.7017e-050.2138image
ENSG00000128394.15,APOBEC3FTHCAAICAREAG3.4396e-050.2016image
chr22:39052977-39055522:+THYMImatinibEER8.9941e-04-0.3030image
chr22:39043328-39044064:+THYMAZD6482EER5.1009e-04-0.5247image
ENSG00000128394.15,APOBEC3FTHYMAZD.0530EAG1.9947e-02-0.2149image
ENSG00000128394.15,APOBEC3FUCECDoxorubicinEAG2.1865e-030.2596image
chr22:39052977-39055522:+UCECAMG.706EER4.8990e-020.1685image
chr22:39043328-39044064:+UCECBosutinibEER1.0004e-030.4392image
chr22:39052977-39055522:+UCSDocetaxelEER3.6677e-020.3830image
ENSG00000128394.15,APOBEC3FUVMBicalutamideEAG2.3331e-04-0.4545image
chr22:39052977-39055522:+UVMBicalutamideEER2.2369e-04-0.4592image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType